This seminal work not only highlights the importance of a balance between PAR synthesis and degradation, but also reveals an entirely new area of research to investigate the roles of PARP in ALT-dependent cancers and extend the potential use of PARP inhibitors, already used against HR-deficient tumors, in the treatment of ALT cancers particularly. Here, PARP1 is linked to cancer.